文献速递血管炎

免疫检查点抑制剂相关血管炎:一种异质性且可能出现严重病程的疾病

Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该多中心回顾性研究通过免疫肿瘤国际登记处(ICIR)识别了28例免疫检查点抑制剂(ICI)暴露后临床和/或影像学怀疑且组织学证实为血管炎的患者,中位诊断间隔4个月,小血管炎占多数(21例);90%需全身糖皮质激素,36%加用其他药物,22例血管炎完全缓解,无患者因血管炎死亡;作者结论认为ICI相关血管炎罕见、异质但可严重,需紧急多学科管理及积极治疗。

要点

  • ICI相关血管炎罕见且异质,小血管炎为主(21/28),诊断距ICI起始中位4个月。
  • 90%患者需全身糖皮质激素,36%加用其他药物;22例完全缓解,无血管炎相关死亡。
  • 仅25%符合2022 ACR/EULAR分类标准;32%再次挑战免疫治疗,仅1例复发。

核心结论

  • ICI相关血管炎罕见、异质,但可严重,需紧急多学科管理及积极治疗。

研究设计与样本

  • 通过免疫肿瘤国际登记处(ICIR)多学科网络回顾性识别ICI暴露后临床和/或影像学怀疑且组织学证实为血管炎的患者。

主要发现

  • 共识别28例,ICI起始至血管炎诊断中位间隔4个月。
  • 小血管炎21例(其中未分类10例、IgA血管炎5例、冷球蛋白性血管炎3例、ANCA+血管炎3例),大血管炎4例,中血管炎3例。
  • 起病时或病程中出现肾脏和神经系统表现各7例(25%),肾活检记录免疫性肾小球病6例。
  • 仅7例(25%)符合2022 ACR/EULAR分类标准(巨细胞动脉炎4例、EGPA 2例、GPA 1例)。
  • 90%患者需全身糖皮质激素,10例(36%)加用其他药物;22例血管炎完全缓解,无患者因血管炎死亡;9例(32%)再次挑战免疫治疗,仅1例复发。

关键数值与推荐

  • 小血管炎21例中包含未分类血管炎10例(局限性皮肤受累6例、系统性受累4例)、IgA血管炎5例、冷球蛋白性血管炎3例、ANCA+血管炎3例。
  • 仅7例(25%)符合2022 ACR/EULAR分类标准:巨细胞动脉炎4例、EGPA 2例、GPA 1例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe presentation, treatment and outcome of immune checkpoint inhibitor (ICI) associated-vasculitis in cancer patients in a multicentre study. METHODS: Thanks to the ImmunoCancer International Registry (ICIR), a multidisciplinary network focused on the research of the immune related adverse events related to cancer immunotherapies, patients presenting with a clinical and/or radiological suspicion of vasculitis and histological evidence of vasculitis after being exposed to ICIs were retrospectively identified. RESULTS: Twenty-eight cases were identified in the ICIR registry. The median interval between starting ICI treatment and vasculitis diagnosis was 4 months. Small vessel vasculitis was predominant (n = 21), followed by large vessel (n = 4) and medium vessel (n = 3). The small vessel vasculitis included 10 unclassified vasculitis either with limited cutaneous involvement (n = 6) or systemic involvement (n = 4), five IgA vasculitis, three cryoglobulinemic vasculitis, and three ANCA+ vasculitis. At presentation or during the evolution, renal and neurologic manifestations were evidenced in seven cases each (25%). Renal biopsies documented immune glomerulopathies in six cases. Only seven patients (25%) fulfilled the 2022 ACR/EULAR classification criteria (four giant cell arteritis, two EGPA and one GPA). Most patients (90%) required systemic corticosteroid and an additional drug was given in 10 patients (36%). Vasculitis outcome was good: 22 patients had vasculitis complete response, no patient died due to vasculitis. Nine patients (32%) were rechallenged with immunotherapy with only one relapse. CONCLUSION: ICI-associated vasculitis are rare, heterogeneous, but can be severe requiring urgent multidisciplinary management with aggressive treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chanson N, Galvagni A, Ramos-Casals M, et al. Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course. Rheumatology (Oxford). 2025. PMID: 39714261. doi:10.1093/rheumatology/keae711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。